blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1

This blog is brougt to you consistent with subsection 3 of the Protection from Harassment Act - i.e. blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1



Monday, 12 April 2010

Seroxat group got legal aid - but still had to pay the doc fees - £500 for Dr Healy or £350 for Dr Ben Green Halton Hospital, UK

yes you still have to pay the doc fees but will set up a payment method. Not a must just now though but let them know you are going to set one up. sorry cant say to much as we have all been told to be quiet.

Saturday, 10 April 2010

Hugh James solicitors "orchestrated the campaign" against GSK Seroxat

SEROXAT SUFFERERS - STAND UP AND BE COUNTED: So clearly the seroxat user group are classed by Mark Harvey as his clients


Mark Harvey of Hugh James solicitors is co-ordinating possible litigation on behalf of UK users. For more information, please visit http://web.archive.org/web/20041011045056/http://www.hughjames.com/dsp_home.cfm or email seroxat@hughjames.com.


Message from Mark Harvey, Hugh James Solicitors

Because of the sheer volume of people still joining the Group Action I am unable to communicate with everyone as frequently as I would like to.However as an update, you should know that during the year the Users Group and I have orchestrated the campaign against the drug and we haveobtained the following victories:-

a) The institution of a Government review into Seroxat; (this has already worked one triumph, a press and public announcement of thedangers of the drug with suicide and the ban of its prescription to minors)

b) The acceptance of the Review team that it will accept the actual evidence of experiences of my clients on Seroxat without needing doctorinvolvement (the mechanics of this are still being addressed)

c) For the first time in the 13 years of this drug, the manufacturers have agreed to change the Patient warning sheets to deal with thequestion of addiction.

With a combination of the preliminary form of self-administered public funding, legal expense insurance and private funding we are progressing the generic investigations and preparing for the appeal on the initial decision to refuse public funding.

The granting of the full publicfunding on appeal will enable us to move forward to the issue of proceedings if necessary. At present the Legal Services Commission tell us the appeal will be September or October however I am challenging them to bring it forward.I will endeavour to keep you informed both through the web site and wherever possible in individual communications. Best wishesMark HarveyHugh James, Solicitors

Thursday, 8 April 2010

Fiddaman's publisher Jason Pegler - a cause for concern see posts on UKsurvivors

58147 Chipmunka offers an extremely nonstandard contract, including:


Chipmunka offers an extremely nonstandard contract, including: - requiring authors to waive moral rights (Chipmunka is a UK-based publisher; the USA doesn't... bryce_j_j

jeremybryce1...

8:09 pm

58148 writers forum members concerned about character of Jason Pegler

Quote: Originally Posted by colealpaugh [View Post]

58149 Chipmunka a vanity project for CEO Jason Pegler


http://mentaldimensions.wordpress.com/2009/01/09/chipmunka-publishing-th\ e-mental-health-publisher/#comment-1568 ...

Blogger claims CEO of Chipmunka publishing is a rapist !

criticalpsychiatry : Message: Blogger claims CEO of Chipmunka publishing is a rapist !



http://chipmunkawatch.blogspot.com/2009/09/jason-pegler-is-rapist.html

Skunk, LSD, Ecstasy & me by Fiddaman's publisher Jason Pegler

uksurvivors : Message: Skunk, LSD, Ecstasy & me by Fiddaman's publisher Jason Pegler

I liked getting stoned immediately.

It made me feel relaxed and amusing, and as though nothing could trouble me.

I also thought smoking cannabis was cool.

Along with my friends, I began to smoke more and more regularly, and by the time I was 15, I was smoking cannabis every day.

And at the weekends, I'd indulge in its stronger sister, skunk.

It gave me such a rush, and I loved the buzz.

The more cannabis I smoked, the cooler I felt I was.

My parents had no idea at all what was going on, and would have been horrified had they known.

Despite being half-comatose a lot of the time, I was able to function pretty much normally at school and around the dinner table, and keep my habit a secret.

By the time I was 16, I had progressed to taking other drugs as well, including LSD and Ecstasy at the weekends.

But cannabis was my favourite drug.

No matter what, I'd start and end the evening with a spliff.

http://groups.yahoo.com/group/uksurvivors/message/58133



Read more: http://www.dailymail.co.uk/femail/article-480208/Descent-madness-High-flyer-driven-psychosis-cannabis.html#ixzz0kVzYkbaq

Wednesday, 7 April 2010

Breggin quits as expert witness - Judge: Testimony by Expert Doesn't Measure Up to 'Frye'


Breggin quits as expert witness - alt.support.breast-implant Google Groups


Pa. Judge: Testimony by Expert Doesn't Measure Up to 'Frye'


Melissa Nann Burke

The Legal Intelligencer

11-12-2004





A Philadelphia judge found an expert's testimony inadmissible in a
medical malpractice case because the methodologies he used "appear to be nothing more than a few anecdotal references and a cursory review of
several studies tangentially related to" the alleged medical basis of
the lawsuit.


After a Frye evidentiary hearing, Common Pleas Judge Jacqueline F. Allen
threw out the report of Peter R. Breggin, a renowned psychiatrist who
extrapolated about possible permanent effects of taking benzodiazepines,
a class of drugs including Valium, Xanax and Ativan that are used as
antianxiety agents, muscle relaxants, sedatives and hypnotics.


"Under Frye [v. United States], novel scientific evidence is admissible
only upon a showing that the methodology has gained general acceptance
in the relevant medical community," Allen wrote in Vinitski v. Adler.
"Breggin's testimony fell well short of the mark."


The judge also found Breggin's expert report to be "legally
insufficient," focusing on the treatment provided by the defendant
doctors "not because it ran counter to the acceptable standards of care
but because it ran counter to Breggin's personal ideas and ideologies of
what the standards should be."

Breggin, from Ithaca, N.Y., is the author of such books as, "Your Drug May Be Your Problem: How and Why to Stop Taking Psychiatric
Medications". He's also written "Toxic Psychiatry: Why Therapy, Empathy
and Love Must Replace the Drug"; "Electroshock and Biochemical Theories
of the 'New Psychiatry;'" and "Talking Back to Prozac: What Doctors
Won't Tell You About Today's Most Controversial Drug."


Breggin's report "draws legal conclusions rather than providing facts
which would allow a fact-finder to come to his own conclusion," Allen
wrote. "A review of the Breggin report does not indicate where and how
the doctors deviated from the standard of care or how harm was created
as a result of the care received."

Allen granted the defendants' motion for summary judgment, dismissing
the case. The plaintiff has appealed the ruling to the Superior Court.

Kevin H. Wright, a defense counsel, said, "This is the type of case that
the Frye and Daubert standards were created to prevent."

Gerald B. Baldino Jr., one of the plaintiff's attorneys, disagreed.

Simon Vinitski had sued the doctors in 2001, alleging that the
combination of medication -- Xanax, Prozac, Valium, Tofranil and
Depakote -- they prescribed and he used intermittently over 10 years to
treat anxiety and depression had caused brain atrophy and other
injuries, according to court documents.


Baldino said his client, a former medical physicist at the Jefferson
Medical College, began to exhibit symptoms like those associated with
Alzheimer's disease, but doctors ruled out that illness and others.

In court, the defendants challenged Breggin's expert opinion. According
to one defendant's motion: "Not only are Dr. Breggin's assertions
condemned by the absence of literature, but also his arguments are
belied by the opinions of other experts in the field of psychiatric
medicine."

Allen held a Frye hearing June 4 to determine whether the report,
examining "whether prolonged exposure to high doses of benzodiazepines
caused permanent brain injury," was inadmissible.

Allen noted that the articles Breggin relied on didn't include relevant
clinical or controlled studies, but instead analyzed other studies that
didn't examine permanent brain damage caused by the drugs. Breggin
admitted his methodologies didn't include treating patients with brain
damage caused by benzodiazepine use or conducting a clinical study of
such patients, according to Allen.

Baldino, who represents Vinitski with attorney Francis J. Curran Jr. of
Curran & Rassias, said this is because testing the combination of drugs
his client used would have required human testing. No clinical studies
of the effects of long-term benzodiazepine use had been conducted, he said.

"But you can look at the effects of short-term use," said Baldino, of
Sacchetta & Baldino. Considering those short-term studies, "Dr. Breggin
extrapolated that the combining of the medications increases the toxic
effect of the drug, and that the result was that Mr. Vinitski suffered
brain damage. He called it a 'toxic cocktail.'"

Allen found that Breggin's opinions were extrapolations. Under the Frye
standard, experts may only extrapolate when the medical inquiry is "new
or the opportunities to examine a specific cause-and-effect relationship
are limited."

That was not the case here, Allen said. Studying the effects of
benzodiazepines isn't new, and there are plenty of people who have been
treated with the drugs to participate in studies about the effects of
its long-term use, she concluded.

"Breggin failed to establish that his variation of an accepted
methodology is generally accepted by scientists in the relevant field as
a method for arriving at his conclusion," she wrote in her opinion
published Sept. 17.

Richard R. Galli, of Goldfein & Joseph, also served as defense counsel.

Saturday, 3 April 2010

Seroxat exclusive - Rob Robinson works for profesionals to bring claims against GSK


click on image to enlarge



source -  SAUK discussion board

thread started by "truthman30" 
headed - Ex Seroxat User
dated - 22 June 2007

post no 37
dated 26 June 2007

Rob Robinson said - "We represent hundreds of clients who have filed claims against GlaxoSmithKline corp for Paxil related injuries."






http://www.social-anxiety-community.org/db/showthread.php?t=17213&page=4




This blog is brougt to you consistent with subsection 3 of the Protection from Harassment Act - i.e. blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1

Wednesday, 31 March 2010

Seroxat - BBC Panorama analysis of e-mails by Charles Medawar

Paroxetine, Panorama and user reporting of
ADRs: Consumer intelligence matters in
clinical practice and post-marketing drug surveillance

http://www.socialaudit.org.uk/IJRSM-161-169.pdf

Charles Medawar a,∗, Andrew Herxheimer b, Andrew Bell c and Shelley Jofre c

a Social Audit Ltd., London, UK bDIPEx Project, Department of Primary Health Care, University of Oxford, Oxford, UKc British Broadcasting Corporation (BBC), London, UK


1. Introduction
An estimated 4.4m people recently watched “Secrets of Seroxat” (Panorama, BBC-TV), a 50-minute
programme about paroxetine, an SSRI antidepressant for which UK general practitioners wrote an estimated 4.7m prescriptions in 2001.


2. Methods
Printouts of the 1,374 Panorama emails (less duplicates) were closely read, and categorized as positive
(234 reports [17%] rated from very positive to “worth taking – just”), negative (647 [48%], rated from
not worth taking to severely disabling), and uncertain (469 [35%], giving no or insufficient evidence
of paroxetine use).

Saturday, 27 March 2010

Genetic test could match mentally ill patients with the best drug

Genetic test could match mentally ill patients with the best drug


The new test will assess whether 26 psychiatric drugs ? including Prozac ? are likely to work or cause side-effects

http://www.timesonline.co.uk/tol/life_and_style/health/mental_health/article7078157.ece


Mark Henderson, Science Editor 1 Comment

Recommend? (3) A genetic test that predicts how patients with mental illnesses such as depression and schizophrenia will respond to drugs is to be offered to British doctors, in a step towards a new era of personalised medicine.



The £1,000 procedure, which is already used in several US hospitals, uses individuals’ DNA to assess whether 26 psychiatric drugs — including Prozac and Seroxat — are likely to work or cause side-effects.



It promises to bring significant improvements to the care of patients with psychiatric conditions, at least a third of whom do not currently benefit from the first drug they are prescribed because they cannot tolerate it or it has no effect.



The development highlights the growing potential of genetics to tailor treatment according to patients’ DNA profiles. This practice, known as pharmacogenetics or pharmacogenomics, is expected to transform many branches of medicine over the next decade, helping doctors to select the therapy that works best for a particular patient.




The psychiatric DNA test, known as GeneSightRx, is offered by the US company AssureRx, which plans to introduce it in Europe by the end of the year.



It is intended for patients who have already proved difficult to treat but could eventually be used by GPs before they prescribe anti-depressants. British experts agreed that such tests could have significant benefits, but cautioned that while the science behind GeneSightRx is sound, there is little evidence yet that it improves patient outcomes.



Peter McGuffin, Professor of Psychiatric Genetics at the Institute of Psychiatry in London, said: “There’s a lot of promise here, and in the long run pharmacogenomics will work, but it’s complex.



“We need evidence that these tests provide an advantage over practice as usual, and in my view that hasn’t been done yet. There is sound science underlying this, but the practicalities have not been looked at in nearly enough detail.”



Donald Singer, Professor of Clincial Pharmacology and Therapeutics at the University of Warwick, said: “At the sharp end of psychiatry, when people are having suicidal thoughts, you really have to get the drug right at the beginning, and a test like this could be very helpful.



“The technology is there, but clinical evidence is the stumbling block: we need to investigate the human element of how it is used and whether it affects patient outcomes.”



Pharmacogenomic tests are founded on the understanding that variations in DNA alter the way that individuals respond to medicines.



Some genes influence the speed with which drugs are metabolised: too fast and a patient may get no benefit, too slow and levels can build up to cause side-effects. Other genes affect the biological receptors on which drugs are designed to work, so that some peoplelack the ability to respond.



GeneSightRx uses a cheek swab to collect DNA, after which five genes are analysed. These are CYP2D6, CYP2C19 and CYP1A2, which affect metabolism, and SLC6A4 and 5HTR2A, which affect serotonin, the brain-signalling chemical on which many psychiatric drugs work. The test was developed by scientists at the Mayo Clinic in Minnesota and Cincinnati Children’s Hospital in Ohio, and is in standard use at both hospitals.



It sorts antipsychotics and antidepressants into three colour-coded groups. A green code indicates drugs that should be safe to use normally, yellow denotes drugs that should be used “with caution”, and red highlights greater risks.



Jim Burns, President of AssureRx, said: “It’s a tool to guide doctors to a medication that might be a better choice for that patient, or to make a dosage adjustment. It is mostly about identifying patients at risk for extreme side-effects: if you cannot tolerate a drug, it will not be useful.”



Caroline Wright, head of science at the PHG Foundation, a genetics think-tank, said the results would be important.“The question is whether such tests improve clinical practice. We don’t yet know whether this actually helps doctors to find the best drug, or whether it’s easier just to try out several different treatments.”



Majorie Wallace, chief executive of the mental health charity SANE, said: “It would be marvellous if there were a way of identifying those people who responded well to certain psychotropic drugs while avoiding giving particular drugs to those for whom it may not be effective or cause distressing side-effects.”



Tailored for a better fit



Warfarin Two genes, CYP2C9 and VKORC1, affect response to the blood-thinning drug given to heart attack and stroke patients. DNA tests can be used to adjust dosage to ensure patients benefit while avoiding potentially fatal bleeding



Abacavir About 6 per cent of people have a gene that makes them hypersensitive to this HIV drug. DNA screening is now recommended before use



Codeine About 10 per cent of Caucasian people have a version of the CYP2D6 gene that means they cannot process the painkiller, and thus derive no benefit



Statins The SLC01B1 gene influences risk of muscle damage while on the cholesterol-lowering drugs. Scientists are investigating whether genetic factors affect which statin is most likely to work



Cancer drugs About 1 in 300 people lacks the gene to metabolise the leukaemia drug 6-mercaptopurine, and thus risk fatal side-effects. Cancer drugs such as Herceptin and Iressa are also tailored to target particular genetic mutations in tumours



Source: Francis Collins, The Language of Life; Times database

Friday, 26 March 2010

GP guidelines recomend suicide check within 9 months of antidep script

The study of 33,483 patients from 88 practices, who had evidence of depression in their notes, found 96 per cent were on antidepressants despite having no recorded episode of depression in the previous two years. There was also evidence GPs were ignoring local guidelines recommending referral and a suicide risk check within nine months of a first depressive episode or antidepressant script.




GPs risk legal action over poor depression notes










03 Aug 03



GPs are failing to keep adequate notes to show they manage patients on antidepressants appropriately.



The findings of a major study prompted a warning from medicolegal experts that GPs could be hauled before the GMC and face legal claims for failing to document their monitoring of patients.



The study of 33,483 patients from 88 practices, who had evidence of depression in their notes, found 96 per cent were on antidepressants despite having no recorded episode of depression in the previous two years. There was also evidence GPs were ignoring local guidelines recommending referral and a suicide risk check within nine months of a first depressive episode or antidepressant script.



Only 10 per cent of 1,391 patients with a recorded episode were referred and 2 per cent had suicide risk recorded, according to results presented to the Society for Academic Primary Care annual conference last month.



Research leader Keith Prescott, educational facilitator in general practice at Queen Mary University of London, said depression's episodic nature made it 'crucial' GPs recorded each episode and reviewed patients.



Lawyers preparing a class action over Seroxat warned in June that any GP appearing to prescribe inappropriately could be vulnerable to legal action.



Dr Stephanie Bown, head of medical services at the Medical Protection Society, said failure to document patient monitoring or what led to an antidepressant script would make it harder for GPs to defend their actions.



'If it's shown you have been irresponsible by continuing to prescribe without showing that patient had been reviewed, you could face a clinical negligence claim and you could find yourself up before the GMC.'



Dr Arnold Zermansky, author of Government guidelines on medication review, said GPs' fears over withdrawing drugs from 'quiet, satisfied patients' and the extra work involved in review could explain why so many with no recent depressive episode were on antidepressants.



The new contract awards 23 quality points for 15-monthly reviews of patients with severe long-term mental health problems

Thursday, 25 March 2010

Fiddaman's Dilemma - A blast from the past, this day 10 years ago.

Dilemma - uk.media.newspapers Google Groups: "what would the going rate be for such a story"

25 Mar 2000

I have been involved with a dispute with my employer's over a disability
issue. Basically, they have put me on a Long Term Absence Register and will
not allow me back to work, not medically retire me or will not let me apply
for voluntary redundancy! They have postponed no less then 4 Industrial
Tribunals and WILL NOT come to an out of court settlement with my legal
advisor. They are a very high profile company who are almost never out of
the news. Would it be advisable for me to go to the press with my story? And
what would the going rate be for such a story bearing in mind that they are
hardly ever out of the news?

http://groups.google.co.uk/group/uk.media.newspapers/browse_thread/thread/d7e6574c676e3a72/5ada06079451c2f6?hl=en&pli=1


--

Bob

Birmingham. UK

ballbreaker...@netscapeonline.co.uk

Sunday, 21 March 2010

How AstraZeneca Is Turning the Tide in Its Legal War Over Antipsychotic Drugs | BNET Pharma Blog | BNET

How AstraZeneca Is Turning the Tide in Its Legal War Over Antipsychotic Drugs BNET Pharma Blog BNET: "How AstraZeneca Is Turning the Tide in Its Legal War Over Antipsychotic Drugs"


AstraZeneca (AZN)’s victory in the first Seroquel lawsuit to go to trial will leave many baffled: How could a company that promoted the antipsychotic drug as better than a generic when it wasn’t; that promoted the drug as “weight neutral” when executives knew it led to weight gain; and that hired staffers who traded sex for study write-ups, possibly be winning the legal war?




The answer can be found in history. America may be a litigious nation, famous for its jackpot hot coffee payouts, but the legal nitty gritty is often far less profitable for plaintiffs than most people think. AZ knew this from the start, and has seemingly relied on it for its so-far successful strategy.



Going in to these cases — there are 10,399 of them — AZ had the benefit of Merck (MRK)’s experience with the painkiller Vioxx. Those cases were far more serious than Seroquel — people died — and at one point Wall Street analysts thought Merck might have to pay $50 billion in costs to plaintiffs. It ended up settling the whole shebang for a tenth of that: Just $4.5 billion.



Merck had advance warning of which way the wind would blow before that settlement came, even though it lost the first case that went to trial. Merck won the appeal of that case. Here’s an old press release summing up the state of the Vioxx litigation before the settlement.



Of the 18 plaintiffs whose cases went to trial, only three have outstanding product liability judgments against Merck.



AZ will have to sit through several more trials and rounds of appeals before it knows what percentage of these cases is likely to succeed. That hasn’t been cheap. Settlements with the government, plus the company’s own legal fees for defending cases, have topped $1.1 billion. But it may just be that AZ has been right all along: There’s no “there” there, at least legally.

Court says thimerosal did not cause autism

The Associated Press: Court says thimerosal did not cause autism: "Court says thimerosal did not cause autism"

By RANDOLPH E. SCHMID (AP) – Mar 12, 2010




WASHINGTON — The vaccine additive thimerosal is not to blame for autism, a special federal court ruled Friday in a long-running battle by parents convinced there is a connection.



While expressing sympathy for the parents involved in the emotionally charged cases, the court concluded they had failed to show a connection between the mercury-containing preservative and autism.



"Such families must cope every day with tremendous challenges in caring for their autistic children, and all are deserving of sympathy and admiration," special master George Hastings Jr. wrote.



But, he added, Congress designed the victim compensation program only for families whose injuries or deaths can be shown to be linked to a vaccine and that has not been done in this case.



The ruling came in the so-called vaccine court, a special branch of the U.S. Court of Federal Claims established to handle claims of injury from vaccines. It can be appealed in federal court.



The parents presented expert witnesses who argued mercury can have a variety of effects on the brain, but the ruling said none of them offered opinions on the cause of autism in the three specific cases argued. They testified that mercury can affect a number of biological processes, including abnormal metabolism in children.



Special master Denise K. Vowell noted that in order to succeed in their action, the parents would have to show "the exquisitely small amounts of mercury" that reach the brain from vaccines can produce devastating effects that far larger amounts ... from other sources do not. The ruling said the parents were arguing that the effects from mercury in vaccines differ from mercury's known effects on the brain. Vowell concluded that the parents had failed to establish that their child's condition was caused or aggravated by mercury from vaccines.



Friday's decision that autism is not caused by thimerosal alone follows a parallel ruling in 2009 that autism is not caused by the combination of vaccines with thimerosal and other vaccines.



The cases had been divided into three theories about a vaccine-autism relationship for the court to consider. The 2009 ruling rejected a theory that thimerasol can cause autism when combined with the measles-mumps-rubella vaccine. After that, a theory that certain vaccines alone cause autism was dropped. Friday's decision covers the last of the three theories, that thimerosal-containing vaccines alone can cause autism.



The ruling doesn't necessarily mean an end to the dispute, however, with appeals to other courts available.



The new ruling was welcomed by Dr. Paul Offit of Children's Hospital of Philadelphia, who said the autism theory had "already had its day in science court and failed to hold up."



But the controversy has cast a pall over vaccines, causing some parents to avoid them, he noted, "it's very hard to unscare people after you have scared them."



On the other side of the issue, a group backing the parents' theory charged that the vaccine court was more interested in government policy than protecting children.



"The deck is stacked against families in vaccine court. Government attorneys defend a government program, using government-funded science, before government judges," Rebecca Estepp, of the Coalition for Vaccine Safety said in a statement.



SafeMinds, another group supporting the parents, expressed disappointment at the new ruling.



"The denial of reasonable compensation to families was based on inadequate vaccine safety science and poorly designed and highly controversial epidemiology," the goup said.



The advocacy group Autism Speaks said "the proven benefits of vaccinating a child to protect them against serious diseases far outweigh the hypothesized risk that vaccinations might cause autism. Thus, we strongly encourage parents to vaccinate their children to protect them from serious childhood diseases."



However, while research has found no overall connection between autism and vaccines, the group said it would back research to determine if some individuals might be at increased risk because of genetic or medical conditions.



Meanwhile, in reaction to the concerns of parents, thimerosal has been removed from most vaccines in the United States.



In Friday's action the court ruled in three different cases, each concluding that the preservative has no connection to autism.



The trio of rulings can offer reassurance to parents scared about vaccinating their babies because of a small but vocal anti-vaccine movement. Some vaccine-preventable diseases, including measles, are on the rise.



The U.S. Court of Claims is different from many other courts: The families involved didn't have to prove the inoculations definitely caused the complex neurological disorder, just that they probably did.



More than 5,500 claims have been filed by families seeking compensation through the government's Vaccine Injury Compensation Program, and the rulings dealt with test cases to settle which if any claims had merit.



Autism is best known for impairing a child's ability to communicate and interact. Recent data suggest a 10-fold increase in autism rates over the past decade, although it's unclear how much of the surge reflects better diagnosis.



Worry about a vaccine link first arose in 1998 when a British physician, Dr. Andrew Wakefield, published a medical journal article linking a particular type of autism and bowel disease to the measles vaccine. The study was later discredited.



Copyright © 2010 The Associated Press. All rights reserved.

Saturday, 20 March 2010

VIOXX - 18 plaintiffs whose cases went to trial, only three have outstanding product liability judgments against Merck

Merck Wins Appeal of First VIOXX® Case to go to Trial


Merck Also Wins Appeals of Major Aspects of New Jersey Cases

WHITEHOUSE STATION, N.J., May 29, 2008 - Merck & Co., Inc. said today that it is gratified that a Texas appeals court overturned the August 2005 verdict of a state court jury in Brazoria County and rendered a judgment in favor of Merck in the VIOXX product liability case Ernst v. Merck. It was the first VIOXX case to go to trial after the Company voluntarily removed the medicine from the market.



Merck also said today that a New Jersey appellate division has overturned the punitive damage and consumer fraud awards in the 2006 verdict in a two-plaintiff VIOXX trial involving Thomas Cona and John McDarby.



"We are gratified that the Texas appeals court correctly found that VIOXX did not cause Mr. Ernst's death and reversed the previous decision for the plaintiff in the first VIOXX case to go to trial. In addition, the New Jersey court correctly reversed the awards of punitive damage and consumer fraud. Today's decisions overturn almost $40 million of damages and attorneys fees previously awarded to plaintiffs at trial," said Bruce Kuhlik, executive vice president and general counsel of Merck & Co., Inc. "We intend to seek further review of the portion of the award that remains standing after the New Jersey decision. We continue to believe Merck acted responsibly."



Ernst Decision

The Texas Fourteenth Court of Appeals found that VIOXX did not cause the death of Mr. Ernst, reversed the jury's verdict and rendered a judgment in favor of Merck.



Chief Justice Adele Hedges, writing for a unanimous panel, said in the ruling, "we find no evidence that Ernst suffered a thrombotic cardiovascular event, i.e., a myocardial infarction triggered by a blood clot. Accordingly, appellee failed to show that ingestion of VIOXX caused her husband's death."



The jury's original verdict on Aug. 19, 2005 included $24,450,000 in compensatory damages and $229,000,000 in punitive damages for a total of $253,425,000 against Merck. On June 23, 2006, based on relevant Texas law which limits the amount of punitive damages, the punitive damage verdict of $229,000,000 was reduced to $1,650,000.



Cona/McDarby Decision

In the Cona and McDarby cases, the New Jersey Appellate Division, an intermediate appellate court, overturned the punitive damage award as well as the consumer fraud award, and let stand the compensatory damages for personal injury to Mr. McDarby. In reversing the consumer fraud verdict, the court also rejected the attorneys fees granted to the plaintiffs' attorneys.



As a result, the court overturned more than $13 million in damages and attorneys fees.



In the trial, which resulted in a partial victory for Merck, the Company presented evidence that both of the heart attacks were caused, not by VIOXX, but by the pre-existing medical conditions of the two men. While the jury found that VIOXX did not cause Mr. Cona's heart attack, it found in favor of Mr. McDarby, awarding him both compensatory and punitive damages.



The jury awarded both men the out of pocket costs associated with their purchases of VIOXX under the consumer fraud statute. Today's decision overturns that award as well.



Status of Litigation

Merck has won the large majority of cases that have gone to trial and thousands of lawsuits have been dismissed. Of the 18 plaintiffs whose cases went to trial, only three have outstanding product liability judgments against Merck.



Merck has entered into an agreement to resolve state and federal myocardial infarction and ischemic stroke claims filed or tolled by Nov. 9, 2007. The settlement program is progressing in a satisfactory manner. Because of the large number of enrollments received so far, Merck is confident that the number of verified enrollments will exceed the thresholds that will obligate the Company to pay $4.85 billion into a resolution fund.



During the Ernst trial, which led to a verdict on Aug. 19, 2005, Merck was represented by Gerry Lowry of Fulbright & Jaworski, L.L.P. of Houston and David C. Kiernan of Williams & Connolly, L.L.P. of Washington D.C. Merck's appellate counsel are Katherine D. Mackillop of Fulbright & Jaworski L.L.P. in Houston and Charles C. Lifland of O'Melveny & Myers LLP in Los Angeles.



Merck's appellate counsel in the Cona and McDarby cases are Douglas S. Eakeley of Lowenstein, Sandler LLP and Charles C. Lifland of O'Melveny & Myers LLP in Los Angeles.



Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the risk factors and cautionary statements in Item 1A of Merck's Form 10-K for the year ended Dec. 31, 2007, and in any risk factors or cautionary statements contained in the Company's periodic reports on Form 10-Q or current reports on Form 8-K, which the Company incorporates by reference.


http://www.merck.com/newsroom/news-release-archive/corporate/2008_0529a.html

Parents of suicidal children get 15% to 40% of Seroxat prescription cost

After attorneys' fees and the costs of administering the settlement are deducted from the $40 million, the balance will be distributed to Class members who qualify and submit a claim as described below. The Class member's submission must certify, as provided in the claim form, that the member is seeking only the member's actual out-of-pocket and unreimbursed cost, based on the amount paid by the Class member, exclusive of any co-payments, deductibles, or other amounts not paid by the member to determine your actual costs for Paxil® prescribed for persons under the age of 18, between January 1, 1998 and December 31, 2004. If the records show a diagnosis of Major Depressive Disorder, the claim amount is calculated at 40% of the actual costs. Otherwise, the claim amount will be 15% of the actual costs.






http://www.pediatricpaxiltppsettlement.com/faq.htm

Seroxat settlement sought $600 million - got $40 million fromm GSK

GSK has entered into a proposed settlement with the Plaintiffs and has agreed to pay $40 million to settle the claims set forth in Plaintiffs' lawsuits as follows:




After attorneys' fees and the costs of administering the settlement are deducted from the $40 million, the balance will be distributed to Class members who qualify and submit a claim as described below. The Class member's submission must certify, as provided in the claim form, that the member is seeking only the member's actual out-of-pocket and unreimbursed cost, based on the amount paid by the Class member, exclusive of any co-payments, deductibles, or other amounts not paid by the member to determine your actual costs for Paxil® prescribed for persons under the age of 18, between January 1, 1998 and December 31, 2004. If the records show a diagnosis of Major Depressive Disorder, the claim amount is calculated at 40% of the actual costs. Otherwise, the claim amount will be 15% of the actual costs.


http://www.pediatricpaxiltppsettlement.com/faq.htm

Pediatric Paxil Third-Party Payor Settlement

Pediatric Paxil Third-Party Payor Settlement: "Pediatric Paxil Third-Party Payor Settlement"


http://www.pediatricpaxiltppsettlement.com/faq.htm

extract -

7. What does the settlement provide?




GSK has entered into a proposed settlement with the Plaintiffs and has agreed to pay $40 million to settle the claims set forth in Plaintiffs' lawsuits as follows:



After attorneys' fees and the costs of administering the settlement are deducted from the $40 million, the balance will be distributed to Class members who qualify and submit a claim as described below. The Class member's submission must certify, as provided in the claim form, that the member is seeking only the member's actual out-of-pocket and unreimbursed cost, based on the amount paid by the Class member, exclusive of any co-payments, deductibles, or other amounts not paid by the member to determine your actual costs for Paxil® prescribed for persons under the age of 18, between January 1, 1998 and December 31, 2004. If the records show a diagnosis of Major Depressive Disorder, the claim amount is calculated at 40% of the actual costs. Otherwise, the claim amount will be 15% of the actual costs.



If the total amount of qualified claims exceeds the available funds, claims will be reduced pro rata. If there is money left over after all claims are paid, the balance up to one million dollars will be donated to a charity involved with childrens' mental health issues. Any remainder of funds, after the charitable donation, shall be allocated to increase the amount payable to class members who have submitted qualifying claims, on a pro rata basis based upon the total pediatric Paxil expenditures during the class period that remain uncompensated after the initial claims process, without regard to diagnoses of the presence or absence of diagnostic information in any Class Member’s claims form.

American lawyers seek $600 million on childrens Seroxat refund - but did they get it?

The drug was not officially sanctioned by US regulator the food and drug administration for use in under-18s. But doctors were allowed to use their own judgment, based on information letters sent by GSK. The lawsuit claims some of these letters omitted the negative information about the drug.




The class action lawsuit was filed in a Minnesota district court last month and is a federal case. The lead plaintiff, Nancy Gerdts, bought the drug for her 12-year-old son in August 2002 and is attempting to get her money back.



Because the law firm is still targeting the thousands of people who bought the drug, the amount the class action is seeking to recover is not yet known. Mr Dahlberg said he estimated the claim could be worth as much as $600m.



Class action lawsuits relating to drugs have been increasingly common in the US, particularly those involving serotonin reuptake inhibitors, which include Prozac and Seroxat
http://www.guardian.co.uk/business/2004/sep/06/medicineandhealth.mentalhealth

American parents sue GSK over Seroxat - seeking prescription cost refund

American parents sue GSK over Seroxat

Heather Tomlinson The Guardian, Monday 6 September 2004 09.15 BST Article history

A lawsuit has been filed against GlaxoSmithKline in the United States seeking refunds for children and adolescents given the antidepressant, Seroxat, following claims that the firm suppressed data showing the drug did not work and increased suicidal tendencies in young people.




The class action suit follows an inquiry by New York state attorney general Eliot Spitzer that made similar accusations.



Last month GSK settled with Mr Spitzer for $2.5m (£1.4m), without admitting liability.



The amount surprised the industry because Mr Spitzer had originally said he wanted to recover all the money GSK had made from selling Seroxat - named Paxil in the US - which analysts have estimated at about £200m.

http://www.guardian.co.uk/business/2004/sep/06/medicineandhealth.mentalhealth